Literature DB >> 16493159

Difficult asthma.

Mary E Strek1.   

Abstract

The correct diagnosis of asthma is usually easily made and most patients with asthma respond to therapy. Approximately 5% of patients with asthma, however, have disease that is difficult to control despite taking maximal doses of inhaled medications. Patients with therapy-resistant or difficult-to-control asthma require a rigorous and systematic approach to their diagnosis and treatment. The first step is evaluation and testing directed at determining that asthma is the correct diagnosis. Many diseases mimic asthma and these alternate diagnoses should be considered. The second step is to identify and eliminate triggers that worsen asthma. Cigarette smoking, occupational exposures, and allergic rhinitis contribute to worsening disease. Most patients with "difficult asthma" require treatment with high-dose inhaled corticosteroids and long-acting inhaled beta(2)-agonists. Despite maximal inhaled therapy, these patients will require either frequent bursts or chronic daily therapy with oral corticosteroids. These patients may have "resistant" inflammation with a persistent inflammatory state. Numerous studies also suggest that compliance with asthma therapy is poor. Combination therapy with inhaled corticosteroids and long-acting beta(2)-agonist in a single inhaler may improve patient compliance. In selected patients, additional therapy with leukotriene modifiers or anti-IgE antibody can result in improved asthma control and may allow tapering of corticosteroids. Use of methotrexate is not justified based on current data. Emerging evidence suggests that different phenotypes of difficult or therapy-resistant asthma exist. Recognition of these subgroups allows tailored therapy and prevents overmedication in an attempt to normalize lung function in patients with irreversible airflow obstruction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16493159     DOI: 10.1513/pats.200510-115JH

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  7 in total

1.  Mesenchymal stromal cells mediate Aspergillus hyphal extract-induced allergic airway inflammation by inhibition of the Th17 signaling pathway.

Authors:  Melissa J Lathrop; Elice M Brooks; Nick R Bonenfant; Dino Sokocevic; Zachary D Borg; Meagan Goodwin; Roberto Loi; Fernanda Cruz; Chad W Dunaway; Chad Steele; Daniel J Weiss
Journal:  Stem Cells Transl Med       Date:  2014-01-16       Impact factor: 6.940

2.  Safety and feasibility of bronchial thermoplasty in asthma patients with very severe fixed airflow obstruction: a case series.

Authors:  Diana C Doeing; Amit K Mahajan; Steven R White; Edward T Naureckas; Jerry A Krishnan; Douglas K Hogarth
Journal:  J Asthma       Date:  2012-12-20       Impact factor: 2.515

Review 3.  Bronchial thermoplasty for the treatment of asthma.

Authors:  Neil Martin; Ian D Pavord
Journal:  Curr Allergy Asthma Rep       Date:  2009-01       Impact factor: 4.806

4.  Acupuncture treatment of a patient with persistent allergic rhinitis complicated by rhinosinusitis and asthma.

Authors:  Ae-Ran Kim; Jun-Yong Choi; Jong-In Kim; So-Young Jung; Sun-Mi Choi
Journal:  Evid Based Complement Alternat Med       Date:  2011-02-10       Impact factor: 2.629

5.  Evaluation of proficiency in using different inhaler devices among intern doctors.

Authors:  Ravish M Kshatriya; Nimit V Khara; Rajiv P Paliwal; Satish N Patel
Journal:  J Family Med Prim Care       Date:  2016 Apr-Jun

6.  Accreditation of specialized asthma units for adults in Spain: an applicable experience for the management of difficult-to-control asthma.

Authors:  Carolina Cisneros; Rocío Magdalena Díaz-Campos; Núria Marina; Carlos Melero; Alicia Padilla; Silvia Pascual; Celia Pinedo; Andrea Trisán
Journal:  J Asthma Allergy       Date:  2017-05-09

7.  CD11b+ and Sca-1+ Cells Exert the Main Beneficial Effects of Systemically Administered Bone Marrow-Derived Mononuclear Cells in a Murine Model of Mixed Th2/Th17 Allergic Airway Inflammation.

Authors:  Fernanda F Cruz; Zachary D Borg; Meagan Goodwin; Amy L Coffey; Darcy E Wagner; Patricia R M Rocco; Daniel J Weiss
Journal:  Stem Cells Transl Med       Date:  2016-03-01       Impact factor: 6.940

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.